» Articles » PMID: 21481788

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

Overview
Journal Cancer Cell
Publisher Cell Press
Specialty Oncology
Date 2011 Apr 13
PMID 21481788
Citations 471
Authors
Affiliations
Soon will be listed here.
Abstract

Physiological levels of Kras(G12D) are sufficient to induce pancreatic intraepithelial neoplasias (PanINs); the mechanisms that drive PanIN progression are unknown. Here, we establish that, in addition to oncogenic Kras(G12D), IL-6 transsignaling-dependent activation of Stat3/Socs3 is required to promote PanIN progression and pancreatic ductal adenocarcinoma (PDAC). Myeloid compartment induces Stat3 activation by secreting IL-6; consequently, IL-6 transsignaling activates Stat3 in the pancreas. Using genetic tools, we show that inactivation of IL-6 transsignaling or Stat3 inhibits PanIN progression and reduces the development of PDAC. Aberrant activation of Stat3 through homozygous deletion of Socs3 in the pancreas accelerates PanIN progression and PDAC development. Our data describe the involvement of IL-6 transsignaling/Stat3/Socs3 in PanIN progression and PDAC development.

Citing Articles

Inflammation, microbiota, and pancreatic cancer.

Chen X, Sun F, Wang X, Feng X, Aref A, Tian Y Cancer Cell Int. 2025; 25(1):62.

PMID: 39987122 PMC: 11847367. DOI: 10.1186/s12935-025-03673-6.


Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis.

Cau R, Saba L Cardiovasc Diagn Ther. 2025; 14(6):1186-1201.

PMID: 39790197 PMC: 11707487. DOI: 10.21037/cdt-24-344.


Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.

Chen Y, Luo Y, Liu Y, Luo D, Liu A Cancer Immunol Immunother. 2025; 74(2):52.

PMID: 39752010 PMC: 11699076. DOI: 10.1007/s00262-024-03899-9.


Plasticity and Tumor Microenvironment in Pancreatic Cancer: Genetic, Metabolic, and Immune Perspectives.

Hashimoto A, Hashimoto S Cancers (Basel). 2024; 16(23).

PMID: 39682280 PMC: 11640101. DOI: 10.3390/cancers16234094.


Unravelling the druggability and immunological roles of the SOCS-family proteins.

Lynch D, Forrester B, Webb T, Ciulli A Front Immunol. 2024; 15:1449397.

PMID: 39676878 PMC: 11638205. DOI: 10.3389/fimmu.2024.1449397.